Mode
Text Size
Log in / Sign up

Clinic workflow, not outreach method, linked to genetic testing rates in high-risk patients

Clinic workflow, not outreach method, linked to genetic testing rates in high-risk patients
Photo by Prasesh Shiwakoti (Lomash) / Unsplash
Key Takeaway
Consider that clinic workflow access may impact genetic testing rates more than outreach method in high-risk patients.

This cohort study evaluated genetic testing participation among high-risk patients (personal or family history of breast or ovarian cancer) at eight Providence Health and Services clinics in California. The outreach evaluation (n=7,112) used a randomized component to compare three methods: mailed brochure, email, and SMS text message. The workflow evaluation (n=16,965) used a retrospective component to compare testing offered in the same building versus requiring patients to go to a different building.

For outreach, the overall genetic testing order rate was less than 3%, and this low rate did not differ significantly between the three outreach methods. For workflow, the genetic testing order rate was 28% lower in the different building workflow compared to the same building workflow (IRR = 0.72, 95% CI = 0.65–0.80). The analysis also found that differences in testing rates by patient characteristics were larger in the different building workflow.

Safety and tolerability data were not reported. A key limitation is that the workflow analysis was retrospective and observational, which limits causal inference. The outreach results come from a randomized comparison, but the overall participation was very low regardless of method.

In practice, these findings suggest that low-cost outreach methods like email are feasible but may have limited impact when participation is very low. The results point to point-of-care access in the same building as potentially critical for improving participation and equity in genetic testing for high-risk patients. However, the retrospective nature of the workflow analysis means the association should be interpreted cautiously.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Genetic testing enables precision medicine by improving disease risk awareness, prevention, and treatment. Despite national guidelines, fewer than 20% of eligible US patients with a personal or family history of breast or ovarian cancer undergo testing, with notable disparities by race, age, and insurance. Population-scale programs and point-of-care strategies, such as risk assessments during mammography, aim to address these gaps. This study evaluates the effectiveness of three outreach methods and clinic workflow variations on genetic testing participation among high-risk patients. The study was conducted at eight Providence Health and Services clinics in California. To evaluate the effectiveness of three outreach methods on genetic testing participation, high-risk patients were randomized to receive one of three methods: mailed brochure, email, and SMS text message. The effectiveness of two workflows was assessed retrospectively, comparing genetic testing among patients who were offered testing in the same building to those who were required to go to a different building. Descriptive and regression analyses were used to examine associations between outreach and workflow and test order rates. A stratified analysis by workflow was used to further examine associations between patient characteristics and genetic testing. A total of 7,112 patients received outreach methods, and 16,965 were included in the retrospective analysis by workflow. Overall, genetic testing following outreach was low, less than 3%, and did not differ by outreach method. The different building workflow was associated with a lower order rate than the same building workflow (IRR = 0.72, 95% CI = 0.65–0.80). The differences in order rates by patient characteristics were larger in the different building workflow. The findings suggest that while outreach yields low engagement, low-cost methods such as email are feasible, and point-of-care access is critical for improving participation and equity. Health systems should prioritize same-day testing and provider capacity to expand access and reduce barriers.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.